ABT-239

ABT-239 je inverzni agonist H₃-receptor, koji je razvila kompanija Abot. On ima stimulantno i nootropno dejstvo, i bio je istraživan za moguću primenu u tretmanu ADHD, Alchajmerove bolesti, i šizofrenije.^[5][6][7][8] ABT-239 je aktivniji na ljudskom H₃ receptoru od sličnih liganda, npr. tioperamida, ciproksifana, i cipralisanta. Razvoj je zaustavljen nakon što je tokom kliničkih ispitivanja pokazano da proizvodi ozbiljne srčane nuspojave QT prolongacije,^[9] ali je još uvek u širokoj upotrebi u životinjskim studijama H₃ antagonista / inverznih agonista.

ABT-239

(IUPAC) ime
4-(22-[(2R)-2-Metilpirolidin-1-il]etil benzofuran-5-il)benzonitril
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem[1][2]	9818903
ChemSpider[3]	7994652
ChEMBL[4]	CHEMBL351231 Y
Hemijski podaci
Formula	C22H22N2O
Mol. masa	330,42 g/mol
SMILES	eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Reference

1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
5. Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA (2005). „Pharmacological properties of ABT-239 [4-(22-[(2R)-2-Methylpyrrolidinyl]ethylbenzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H₃ receptor antagonist with drug-like properties”. J. Pharmacol. Exp. Ther. 313 (1): 165–75. DOI:10.1124/jpet.104.078303. PMID 15608078.
6. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA (2005). „Pharmacological properties of ABT-239 [4-(22-[(2R)-2-Methylpyrrolidinyl]ethylbenzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H₃ receptor antagonist”. J. Pharmacol. Exp. Ther. 313 (1): 176–90. DOI:10.1124/jpet.104.078402. PMID 15608077.
7. Cowart M, Faghih R, Curtis MP, Gfesser GA, Bennani YL, Black LA, Pan L, Marsh KC, Sullivan JP, Esbenshade TA, Fox GB, Hancock AA (2005). „4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H₃ receptor antagonists potently enhance cognition and attention”. J. Med. Chem. 48 (1): 38–55. DOI:10.1021/jm040118g. PMID 15634000.
8. Le S, Gruner JA, Mathiasen JR, Marino MJ, Schaffhauser H (June 2008). „Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H₃ receptor antagonists”. J. Pharmacol. Exp. Ther. 325 (3): 902–9. DOI:10.1124/jpet.107.135343. PMID 18305012.
9. Hancock, AA (2006). „The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.”. Biochemical pharmacology 71 (8): 1103–13. DOI:10.1016/j.bcp.2005.10.033. PMID 16513092.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

• MeSH 4-(2-(2-(2-methyl-1-pyrrolidinyl)ethyl)-1-benzofuran-5-yl)benzonitrile